A5020771677- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Inhalation and Respiratory Drug Delivery
- Eosinophilic Esophagitis
- Pediatric health and respiratory diseases
- IL-33, ST2, and ILC Pathways
- Pharmaceutical studies and practices
- Amyotrophic Lateral Sclerosis Research
- COVID-19 and healthcare impacts
- Allergic Rhinitis and Sensitization
- Neurogenetic and Muscular Disorders Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- COVID-19 Clinical Research Studies
- Multiple Myeloma Research and Treatments
- Muscle and Compartmental Disorders
- Renal Transplantation Outcomes and Treatments
- Vaccine Coverage and Hesitancy
- Long-Term Effects of COVID-19
- Family and Patient Care in Intensive Care Units
- Inflammatory Myopathies and Dermatomyositis
- Fibroblast Growth Factor Research
- Immune Cell Function and Interaction
- Barrier Structure and Function Studies
- Acute Lymphoblastic Leukemia research
- Respiratory viral infections research
Amsterdam University Medical Centers
2019-2024
University of Amsterdam
2019-2024
Amsterdam University of the Arts
2023
Health First
2022
University Medical Center
2020
Leiden University Medical Center
2015-2018
Leiden University
2016
Newcastle University
2009
Martin Luther University Halle-Wittenberg
2005
BackgroundPatients with severe eosinophilic asthma show different responses to various anti–IL-5 biologics, ranging from super response nonresponse. Residual disease manifestations observed in partial responders may prompt physicians switch between biologics. More data on response, switches, and residual are needed improve personalized treatment.ObjectiveTo assess (1) prevalences predictors of super, partial, nonresponders long-term treatment, (2) frequency reasons for switches (3) nature...
The major complication of COVID-19 is hypoxaemic respiratory failure from capillary leak and alveolar oedema. Experimental early clinical data suggest that the tyrosine-kinase inhibitor imatinib reverses pulmonary leak. This randomised, double-blind, placebo-controlled, trial was done at 13 academic non-academic teaching hospitals in Netherlands. Hospitalised patients (aged ≥18 years) with COVID-19, as confirmed by an RT-PCR test for SARS-CoV-2, requiring supplemental oxygen to maintain a...
Clinical Implications•In rare cases, anti–IL-4/13 for severe asthma can cause hypereosinophilia, with sudden deterioration of asthma, eosinophilic tissue infiltration, and granulomatosis polyangiitis–like symptoms. Prednisone-dependent patients who switched from anti–IL-5 to treatment may be particularly at risk these serious complications. •In Currently, 5 biologic therapies have been approved the add-on asthma. They all block type 2 inflammatory pathways, either by targeting IgE...
BackgroundIt is unclear whether asthma and medications increase or decrease the risk of severe COVID-19, this particularly true for patients with receiving biologics.ObjectivesThe aim study was to assess incidence disease course COVID-19 in on biologic therapy (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab), as compared data from general Dutch population.MethodsCOVID-19 cases were identified through a prospective ongoing survey between March 17 April 30, 2020 among all...
Reslizumab, a biologic targeting IL-5, has been shown to reduce asthma exacerbations and maintenance oral corticosteroid use in randomized controlled trials pre-post studies patients with severe eosinophilic asthma. However, real-world effectiveness data of reslizumab are scarce, it is unknown whether added value after switching from another type 2 biologic.To evaluate (1) the on exacerbations, use, overall treatment response, both biologic-naive who initiated those switched biologic; (2)...
Severe asthma is a complex, multidimensional disease. Optimal treatment, adherence and outcomes require shared decision-making, rooted in mutual understanding between patient clinician. This study used novel, patient-centred approach to examine the most bothersome aspects of severe patients, as seen from both perspectives registries.Across seven countries, 126 patients with completed an open-ended survey regarding aspect(s) their asthma. Patients' responses were linked treating clinician who...
Background We have previously developed Core Outcome Measures sets for Severe Asthma (COMSA) by multi-stakeholder consensus. There are no patient-centred tools to quantify response biologics severe asthma. aimed develop paediatric and adult CompOsite iNdexes For Response in asthMa (CONFiRM) incorporating clinical parameters patient-reported quality of life (QoL). Methods International expert healthcare professionals (HCPs) patients with asthma were invited to: 1) consensus levels clinically...
An objective of the Severe Heterogeneous Asthma Registry, Patient-centered (SHARP) is to produce real-world evidence on a pan-European scale by linking nonstandardised, patient-level registry data. Mepolizumab has shown clinical efficacy in randomised controlled trials and prospective studies could therefore serve as proof principle for this novel approach. The aim present study was harmonise data from 10 national severe asthma registries characterise patients receiving mepolizumab, assess...
It is understood that chronic allograft failure occurs as a result of alloimmune and non-alloimmune injury. Dendritic cells (DC) are thought to be crucial in regulating (allo)immune airway damage interactions with epithelial likely. Studies human lung transplantation limited, however, the available literature on DC inconsistent. This study focused ex vivo influence primary bronchial derived from allografts differentiation.Epithelial cell conditioned media (ECCM) were added monocytes...
Asthma patients using high cumulative doses of oral corticosteroids (OCSs) are at risk serious adverse events and increasingly being treated with steroid-sparing asthma biologics. However, it is unknown whether prescribing these expensive biologics always justified.This study aimed to (1) assess the prevalence OCSs, (2) explore role suboptimal inhaler therapy, (3) estimate proportion whom might be prescribed unnecessarily.All adults (n = 5,002) least 1 prescription high-dose inhaled...
Background The coronavirus disease 2019 (COVID-19) pandemic has put pressure on healthcare services, forcing the reorganisation of traditional care pathways. We investigated how physicians taking severe asthma patients in Europe reorganised care, and these changes affected patient satisfaction, control future care. Methods In this European-wide cross-sectional study, surveys were sent to with a physician-diagnosis asthma, physician specialists between November 2020 May 2021. Results 1101 268...
Vaccination is vital for achieving population immunity to severe acute respiratory syndrome coronavirus 2, but vaccination hesitancy presents a threat widespread immunity. Vaccine acceptance in chronic potentially immunosuppressed patients largely unclear, especially with asthma. The aim of this study was investigate the experience people asthma.Questionnaires about beliefs (including Attitudes Examination (VAX) scale, measure hesitancy-related beliefs), side-effects, asthma control and...
Recent studies have highlighted the role of impaired barrier function and aberrant epithelial cell responses in pathogenesis allergy asthma. Epidemiological showed that children growing up on farms a lower incidence childhood asthma, which was attributed to high microbial exposure. Interestingly, exposure found enhance gut maintain homeostasis. Therefore, we hypothesized microbe-rich environment present farm dust may similar barrier-enhancing effect airway epithelium. In this study, extracts...
<b>Background:</b> Asthma patients using high doses of oral corticosteroids are exposed to serious adverse effects. It is therefore important know the prevalence and characteristics these patients, as this may help physicians find appropriate measures therapies reduce use harmful drugs. <b>Aim:</b> We assessed asthma high-dose corticosteroids, investigate whether was justified, estimate proportion eligible for steroid-sparing biologics. <b>Methods:</b> A pharmacy database containing data...
<b>Background:</b> Reslizumab, an anti-interleukin-5 biologic, reduces asthma exacerbations and maintenance oral glucocorticoid use in randomized controlled trials pre-post studies patients with severe eosinophilic asthma. However, real-world effectiveness data of reslizumab are scarce. <b>Aim:</b> To evaluate the on exacerbations, corticoid dose, overall treatment response, both biologic naïve initiators, who had switched from another type-2 biologic. <b>Methods:</b> Changes exacerbation...